| Focus: | To revolutionize health care by focusing on all areas related to the development of molecular imaging probes - chemical compounds that provide a non-invasive means to diagnose disease at its earliest stage. |
| Funding: | $14,955,575 for entire funding period |
| Strength: | One patent filed |
| Partnership Power: | $3,373,311 in cash & in-kind contributions |
| Scientific Director and CEO: | Dr. John Valliant |
| Web site: |